Browsing by Author "Omer F.A.A."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Beta-mangostin demonstrates apoptogenesis in murine leukaemia (WEHI-3) cells in vitro and in vivo(BioMed Central Ltd., 2017) ;Omer F.A.A. ;Hashim N.M. ;Ibrahim M.Y. ;Aldoubi A.F. ;Hassandarvish P. ;Dehghan F. ;Nordin N. ;Karimian H. ;Salim L.Z.A. ;Abdulla M.A. ;Al-Jashamy K. ;Mohan S. ;Faculty of Medicine and Health Sciences ;University of Malaya (UM) ;Universiti Sains Islam Malaysia (USIM) ;SEGi University CollegeJazan UniversityBackground: Beta-mangostin (BM) is a xanthone-type of natural compound isolated from Cratoxylum arborescens. This study aimed to examine the apoptosis mechanisms induced by BM in a murine monomyelocytic cell line (WEHI-3) in vitro and in vivo. Methods: A WEHI-3 cell line was used to evaluate the cytotoxicity of BM by MTT. AO/PI and Hoechst 33342 dyes, Annexin V, multiparametric cytotoxicity 3 by high content screening (HCS); cell cycle tests were used to estimate the features of apoptosis and BM effects. Caspase 3 and 9 activities, ROS, western blot for Bcl2, and Bax were detected to study the mechanism of apoptosis. BALB/c mice injected with WEHI-3 cells were used to assess the apoptotic effect of BM in vivo. Results: BM suppressed the growth of WEHI-3 cells at an IC50value of 14 � 3 ?g/mL in 24 h. The ROS production was increased inside the cells in the treated doses. Both caspases (9 and 3) were activated in treating WEHI-3 cells at 24, 48 and 72 h. Different signs of apoptosis were detected, such as cell membrane blebbing, DNA segmentation and changes in the asymmetry of the cell membrane. Another action by which BM could inhibit WEHI-3 cells is to restrain the cell cycle at the G1/G0 phase. In the in vivo study, BM reduced the destructive effects of leukaemia on the spleen and liver by inducing apoptosis in leukaemic cells. Conclusion: BM exerts anti-leukaemic properties in vitro and in vivo. � 2017 The Author(s). - Some of the metrics are blocked by yourconsent settings
Publication Plagioneurin B, a potent isolated compound induces apoptotic signalling pathways and cell cycle arrest in ovarian cancer cells(Springer New York LLC, 2018) ;Nordin N. ;Majid N.A. ;Othman R. ;Omer F.A.A. ;Nasharuddin M.N.A. ;Hashim N.M. ;Faculty of Medicine and Health Sciences ;Universiti Sains Islam Malaysia (USIM) ;University of Malaya (UM)Universiti Putra Malaysia (UPM)Plagioneurin B belongs to acetogenin group has well-established class of compounds. Acetogenin group has attracted worldwide attention in the past few years due their biological abilities as inhibitors for several types of tumour cells. Plagioneurin B was isolated via conventional chromatography and tested for thorough mechanistic apoptosis activity on human ovarian cancer cells (CAOV-3). Its structure was also docked at several possible targets using Autodock tools software. Our findings showed that plagioneurin B successfully inhibits the growth of CAOV-3 cells at IC50 of 0.62��M. The existence of apoptotic bodies, cell membrane blebbing and chromatin condensation indicated the hallmark of apoptosis. Increase of Annexin V-FITC bound to phosphatidylserine confirmed the apoptosis induction in the cells. The apoptosis event was triggered through the extrinsic and intrinsic pathways via activation of caspases 8 and 9, respectively. Stimulation of caspase 3 and the presence of DNA ladder suggested downstream apoptotic signalling were initiated. Further confirmation of apoptosis was conducted at the molecular levels where up-regulation in Bax, as well as down-regulation of Bcl-2, Hsp-70 and survivin were observed. Plagioneurin B was also seen to arrest CAOV-3 cells cycle at the G2/M phase. Docking simulation of plagioneurin B with CD95 demonstrated that the high binding affinity and hydrogen bonds formation may explain the capability of plagioneurin B to trigger apoptosis. This study is therefore importance in finding the effective compound that may offer an alternative drug for ovarian cancer treatment. � 2018, Springer Science+Business Media, LLC, part of Springer Nature.